Navigation Links
BrainStorm CEO to Present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum
Date:3/22/2017

HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 22, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide an update on new developments and a corporate overview at Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum, being held on March 27th at the New York Academy of Sciences.

Neuroscience Biopartnering and Investment Forum Presentation Details Date:      

Monday, March 27Time:             

2:20pm Eastern TimeLocation:       

New York Academy of Sciences, 7 World Trade Center

About the Annual Neuroscience BioPartnering & Investment ForumThe 2nd Annual Neuroscience BioPartnering & Investment Forum to take place on 27th of March at the New York Academy of Sciences. It will focus on key areas of neurodegenerative diseases and pain management with a mix of specialist panels and company presentations. The event is targeted at buy and sell side analysts from investment banks and funds and partnering executives from pharma. For more information, refer to http://www.sachsforum.com/2nbpi-about.html

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo.  For more information, visit the company's website at www.brainstorm-cell.com.

CONTACTSMedia:
Uri Yablonka
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-ceo-to-present-at-the-sachs-associates-2nd-annual-neuroscience-biopartnering-and-investment-forum-300427336.html


'/>"/>
SOURCE BrainStorm Cell Therapeutics Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
2. BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
3. BrainStorm Hosting Conference Call to Update Shareholders on Important Developments
4. BrainStorm Awarded Additional $735,000 Non-Dilutive Grant for 2015 from Israels Office of the Chief Scientist
5. BrainStorm Cell Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update
6. BrainStorm Cell Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa
7. BrainStorm Cell Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
8. BrainStorm Cell Therapeutics to Report Second Quarter 2015 Financial Results on Thursday, August 13
9. BrainStorm Cell Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14
10. BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israels Chief Scientist Office
11. BrainStorm Cell Therapeutics to Report Third Quarter 2014 Financial Results on Thursday, November 13
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... NJ (PRWEB) , ... June 20, 2017 , ... Do ... makes the transition from being a trusted supplier in the weighing industry, to extending ... cell extractions, ELISA essays, enzyme reactions, immunoassays, hybridizations and more, allowing for its ...
(Date:6/19/2017)... ... , ... Tunnell Consulting has been solving the most complex problems ... faced by life sciences, biotech and pharmaceuticals companies today is in interpreting the complicated ... who is well known in the industry and brings significant high-level expertise to the ...
(Date:6/16/2017)... ... ... CTNext , Connecticut’s go-to resource for entrepreneurial support, today announced the ... Piers in Stamford. , Nine finalists, all of whom are Connecticut-based companies and entrepreneurs, ... secure $10,000 awards to help support business growth. The winners included:, ...
(Date:6/15/2017)... ... June 15, 2017 , ... angelMD announced the ... startup. Dan Parsley, angelMD’s SVP of Corporate Development, served as the syndicate leader ... is part of Saranas’ recently announced $4 million Series B financing round. , ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):